Filing Flows › Alnylam Pharmaceuticals (ALNY) › ONPATTRO revenue
Alnylam Pharmaceuticals (ALNY) ONPATTRO revenue by quarter
Alnylam Pharmaceuticals' ONPATTRO revenue was $19.6M in Q3 2026 (third quarter 2026), +6% from Q2 2026. Over the last 7 quarters it ranged from $18.5M (Q2 2026) to $56.1M (Q4 2024).
| Quarter | ONPATTRO revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $19.6M | +6% | -50% |
| Q2 2026 | $18.5M | -42% | -65% |
| Q4 2025 | $31.7M | -19% | -44% |
| Q3 2025 | $39.1M | -26% | — |
| Q2 2025 | $52.5M | +6% | — |
| Q1 2025 | $49.5M | -12% | — |
| Q4 2024 | $56.1M | — | — |
Q3 2026 at a glance
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
Questions
What is Alnylam Pharmaceuticals' ONPATTRO revenue?
Alnylam Pharmaceuticals' ONPATTRO revenue was $19.6M in Q3 2026 (third quarter 2026), +6% from Q2 2026.
How has Alnylam Pharmaceuticals' ONPATTRO revenue changed?
Over the last 7 quarters it ranged from $18.5M (Q2 2026) to $56.1M (Q4 2024).
Q3 2026 results → · How Alnylam Pharmaceuticals makes money →